Author:
Ye Jingrong,Chen Jing,Wang Juan,Wang Yuncong,Xing Hui,Yu Fengting,Liu Lifeng,Han Yang,Huang Huihuang,Feng Yi,Ruan Yuhua,Zheng Minna,Lu Xinli,Guo Xiaoli,Yang Hong,Guo Qi,Lin Yi,Wu Jianjun,Wu Shouli,Tang Yilong,Sun Xiaoguang,Zou Xiaobai,Yu Guolong,Li Jianjun,Zhou Quanhua,Su Ling,Zhang Lincai,Gao Zhan,Xin Ruolei,He Shufang,Xu Conghui,Hao Mingqiang,Hao Yinxiao,Ren Xianlong,Li Jie,Bai Lishi,Jiang Tianjun,Zhang Tong,Shao Yiming,Lu Hongyan
Abstract
AbstractHIV subtypes convey important epidemiological information and possibly influence the rate of disease progression. In this study, HIV disease progression in patients infected with CRF01_AE, CRF07_BC, and subtype B was compared in the largest HIV molecular epidemiology study ever done in China. A national data set of HIV pol sequences was assembled by pooling sequences from public databases and the Beijing HIV laboratory network. Logistic regression was used to assess factors associated with the risk of AIDS at diagnosis ([AIDSAD], defined as a CD4 count < 200 cells/µL) in patients with HIV subtype B, CRF01_AE, and CRF07_BC. Of the 20,663 sequences, 9,156 (44.3%) were CRF01_AE. CRF07_BC was responsible for 28.3% of infections, followed by B (13.9%). In multivariable analysis, the risk of AIDSAD differed significantly according to HIV subtype (OR for CRF07_BC vs. B: 0.46, 95% CI 0.39─0.53), age (OR for ≥ 65 years vs. < 18 years: 4.3 95% CI 1.81─11.8), and transmission risk groups (OR for men who have sex with men vs. heterosexuals: 0.67 95% CI 0.6─0.75). These findings suggest that HIV diversity in China is constantly evolving and gaining in complexity. CRF07_BC is less pathogenic than subtype B, while CRF01_AE is as pathogenic as B.
Funder
Capital's Funds for Health Improvement and Research
Beijing Municipal Natural Science Foundation
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. National Health Commission of the People’s Republic of China. Overview of notifiable infectious diseases nationwide. http://www.nhc.gov.cn/jkj/s3578/202102/2272547b05674a40a030a83eefede958.shtml. Accessed 1 Dec 2020.
2. China Center for Disease Prevention and Control. National progress in the prevention and treatment of AIDS and hepatitis C of China in 2020 and priority areas of work in 2021, National annual meeting on the prevention and treatment of AIDS and hepatitis C of China, Beijing China (2020).
3. Hemelaar, J. et al. Global and regional molecular epidemiology of HIV-1 1990–2015: A systematic review, global survey, and trend analysis. Lancet Infect. Dis. 19, 143–155 (2019).
4. He, X. et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS ONE 7, e47289 (2012).
5. The UK Collaborative Group on HIV Drug Resistance. The increasing genetic diversity of HIV-1 inthe UK, 2002–2010. AIDS. 28, 773–80 (2014).